MeCo Score™

Report Date: MM/DD/YYYY

Patient:	Sample Patient	Ordering Client:	Medical Center
Sex at Birth:	Female	Specimen Type:	FFPE Block
DOB:	MM/DD/YYYY	Specimen Site:	Breast
Medical Record #:	MR 000000	Tumor Collection Date:	MM/DD/YYYY
Client Accession #:	CA 000000	Normal Collection Date:	MM/DD/YYYY
Ordering Physician:	Sample Physician	Received Date:	MM/DD/YYYY

Results Snapshot

Analytes sequenced: whole transcriptome RNA

Actionable targets: Yes

Level of Evidence: NCCN Category TBD

Diagnosis: Invasive breast carcinoma; pT2, pN0, M0
[ER (POSITIVE); PgR (POSITIVE); HER2 (NEGATIVE); Ki-67 (11%)]

KEY BIOMARKER FINDING

KEY BIOMARKER	FDA-APPROVED DRUGS for patient's disease	FDA-APPROVED DRUGS for another disease[1]	COST EFFECTIVE GENERIC DRUG AVAILABILITY	DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT[2]
MeCo Score: **High**		Nintedanib	Yes*	Pembrolizumab

~4X increase in event-free survival at 5 years post-therapy (relative)



CLINICAL SIGNIFICANCE

High MeCo Score patients who received neoadjuvant nintedanib + chemotherapy experienced a substantial and durable benefit compared to those who received chemotherapy alone.

[1]The prescribing information for the FDA-approved therapy option may not include the associated Key Biomarker.

[2]Data sourced from I-SPY 2 neoadjuvant trial platform and on file at MeCo Diagnostics.

*Projected for European market entry in 2024 and US market entry in 2026.

EFS: the length of time after primary treatment that a patient remains free of complications or events that the treatment was intended to prevent or delay.

MeCo Diagnostics Holdings, Inc. 5015 Shoreham Pl, Ste 150, San Diego, CA 92122